Venom immunotherapy for preventing allergic reactions to insect stings

Cochrane Database of Systematic Reviews

Volumn 2012, Issue 10, 2012, Pages

  Boyle, Robert J ^a   Elremeli, Mariam ^a   Hockenhull, Juliet ^b   Cherry, Mary Gemma ^b   Bulsara, Max K ^c   Daniels, Michael ^d   Oude Elberink, J N G ^e  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c UNIVERSITY OF NOTRE DAME   (Australia)

^d UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^e UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; BEE VENOM; WASP VENOM;

ADULT; ANIMAL; ANT; CHILD; DESENSITIZATION; HUMAN; IMMUNOLOGY; INSECT BITE; META ANALYSIS; METHODOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

ADULT; ALLERGENS; ANIMALS; ANTS; BEE VENOMS; CHILD; DESENSITIZATION, IMMUNOLOGIC; HUMANS; INSECT BITES AND STINGS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; WASP VENOMS;

EID: 84871852838     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD008838.pub2     Document Type: Review

References (72)

1. Brown SG, Wiese MD, Blackman KE, Heddle RJ. Ant venom immunotherapy: a double-blind, placebo-controlled, crossover trial. Lancet 2003;361(9362):1001-6.
2. Golden DB, Kelly D, Hamilton RG, Craig TJ. Venom immunotherapy reduces large local reactions to insect stings. Journal of Allergy and Clinical Immunology 2009;123(6):1371-5.
3. Hunt KJ, Valentine MD, Sobotka AK, Benton A, Amodio FJ, Lichtenstein LM. A controlled trial of immunotherapy in insect hypersensitivity. New England Journal of Medicine 1978;299(4):157-61.
4. Oude Elberink JNG, de Monchy JGR, Guyatt GH, Dubois AEJ. Venom immunotherapy improves health-related quality of life in patients with allergic reactions following yellow-jacket stings - extended observations. Journal of Allergy and Clinical Immunology 2001;107(2):S222-3.
5. Oude Elberink JNG, de Monchy JGR, van der Heide S, Guyatt GH, Dubois AEJ. Venom immunotherapy improves health-related quality of life in patients allergic to yellow jacket venom. Journal of Allergy and Clinical Immunology 2002;110(1):174-82.
6. Oude Elberink JNG, van der Heide S, Guyatt GH, Dubois AEJ. Analysis of the burden of treatment in patients receiving an EpiPen for yellow jacket anaphylaxis. Journal of Allergy & Clinical Immunology 2006;118(3):699-704.
7. Oude Elberink JNG, van der Heide S, Guyatt GH, Dubois AEJ. Immunotherapy improves health-related quality of life of adult patients with dermal reactions following yellow jacket stings. Clinical and Experimental Allergy 2009;39(6):883-9.
8. Severino M, Cortellini, G, Bonadonna P, Francescato E, Panzini I, Macchia D, et al. Sublingual immunotherapy with honeybee venom reduces large local reactions: a randomised, double blind controlled study. EAACI Conference Abstract. 2008:A170.
9. Severino MG, Cortellini G, Bonadonna P, Francescato E, Panzini I, Macchia D, et al. Sublingual immunotherapy for large local reactions caused by honeybee sting: a double-blind, placebo-controlled trial. Journal of Allergy and Clinical Immunology 2008;122(1):44-8.
10. Schuberth KC, Lichtenstein LM, Kagey-Sobotka A, Szklo M, Kwiterovich KA, Valentine MD. Epidemiologic study of insect allergy in children. II. Effect of accidental stings in allergic children. Journal of Pediatrics 1983;102(3):361-5.
11. Valentine MD, Schuberth KC, Kagey-Sobotka A, Graft DF, Kwiterovich KA, Szklo M, et al. The value of immunotherapy with venom in children with allergy to insect stings. New England Journal of Medicine 1990;323(23):1601-3.
12. Berchtold E, Maibach R, Müller U. Reduction of side effects from rush-immunotherapy with honey bee venom by pretreatment with terfenadine. Clinical and Experimental Allergy 1992;22(1):59-65.
13. Bilò MB, Severino M, Cilia M, Pio A, Casino G, Ferrarini E, et al. The VISYT trial: Venom Immunotherapy Safety and Tolerability with purified vs nonpurified extracts. Annals of Allergy Asthma and Immunology 2009;103(1):57-61.
14. Bousquet J, Fontez A, Aznar R, Robinet-Levy M, Michel FB. Combination of passive and active immunization in honeybee venom immunotherapy. Journal of Allergy and Clinical Immunology 1987;79(6):947-54.
15. Brockow K, Kiehn M, Riethmüller C, Vieluf D, Berger J, Ring J. Efficacy of antihistamine pretreatment in the prevention of adverse reactions to Hymenoptera immunotherapy: a prospective, randomized, placebo-controlled trial. Journal of Allergy and Clinical Immunology 1997;100(4):458-63.
16. Brown SG, Wiese MD, Chuter CL, Gunner J. Rapid (ultra-rush) versus clustered (semi rush) initiation of insect venom immunotherapy: an open randomised controlled trial with patient choice arms. Internal Medicine Journal 2008;38(S6):A151.
17. Divanovic A, Melac M, Herman D. Cetirizine (20 mg/day) versus placebo in the prevention of reactions secondary to accelerated desensitization to hymenoptera venoms [Cetirizine (20 mg/j) versus placebo dans la prevention des reactions secondaires de la desensibilisation acceleree aux venins d'hymenopteres]. Revue Francaise D'Allergologie Et D'Immunologie Clinique 1997;37(6):741-5.
18. Malling HJ, Djurup R, Søndergaard I, Weeke B. Clustered immunotherapy with yellow jacket venom. Evaluation of the influence of time interval on in vivo and in vitro parameters. Allergy 1985;40(5):373-83.
19. Mosbech H, Malling H J, Biering I, Böwadt H, Søborg M, Weeke B, et al. Immunotherapy with yellow jacket venom. A comparative study including three different extracts, one adsorbed to aluminium hydroxide and two unmodified. Allergy 1986;41(2):95-103.
20. Müller U, Lanner A, Schmid P, Bischof M, Dreborg S, Hoigné R. A double blind study on immunotherapy with chemically modified honey bee venom: monomethoxy polyethylene glycol-coupled versus crude honey bee venom. International Archives of Allergy and Applied Immunology 1985;77(1-2):201-3.
21. Müller U, Rabson AR, Bischof M, Lomnitzer R, Dreborg S, Lanner A. A double-blind study comparing monomethoxy polyethylene glycol-modified honeybee venom and unmodified honeybee venom for immunotherapy. Journal of Allergy and Clinical Immunology 1987;80(3 Pt 1):252-61.
22. Müller U, Helbling A, Berchtold E. Immunotherapy with honeybee venom and yellow jacket venom is different regarding efficacy and safety. Journal of Allergy and Clinical Immunology 1992;89(2):529-35.
23. Müller U, Hari Y, Berchtold E. Premedication with antihistamines may enhance efficacy of specific-allergen immunotherapy. Journal of Allergy and Clinical Immunology 2001;107(1):81-6.
24. Müller UR, Jutel M, Reimers A, Zumkehr J, Huber C, Kriegel C, et al. Clinical and immunologic effects of H1 antihistamine preventive medication during honeybee venom immunotherapy. Journal of Allergy and Clinical Immunology 2008;122(5):1001-7.
25. Öhman S, Björkander J, Dreborg S, Lanner Å, Malling HJ, Weeke B. A preliminary study of immunotherapy with a monomethoxy polyethylene glycol modified honey bee venom preparation. Allergy 1986;41(2):81-8.
26. Quercia O, Rafanelli S, Puccinelli P, Stefanini GF. The safety of cluster immunotherapy with aluminium hydroxide-adsorbed honey bee venom extract. Journal of Investigative Allergology and Clinical Immunology 2001;11(1):27-33.
27. Reimers A, Hari Y, Müller U. Reduction of side-effects from ultrarush immunotherapy with honeybee venom by pretreatment with fexofenadine: a double-blind, placebo-controlled trial. Allergy 2000;55(5):484-8.
28. Roumana A, Pitsios C, Vartholomaios S, Kompoti E, Kontou-Fili K. The safety of initiating Hymenoptera immunotherapy at 1 mug of venom extract. Journal of Allergy and Clinical Immunology 2009;124(2):379-81.
29. Spertini F, Fellrath JM, Kettner A, Dufour N, Frigerio C, Schneeberger D, et al. Allergen-derived long peptide immunotherapy in bee venom hypersensitive patients. Allergologie 2000;23(3):156.
30. Thurnheer U, Müller U, Stoller R, Lanner A, Hoigné R. Venom immunotherapy in hymenoptera sting allergy. Comparison of rush and conventional hyposensitization and observations during long-term treatment. Allergy 1983;38(7):465-73.
31. Wöhrl S, Gamper S, Hemmer W, Heinze G, Stingl G, Kinaciyan T. Premedication with montelukast reduces local reactions of allergen immunotherapy. International Archives of Allergy and Immunology 2007;144(2):137-42.
32. Zubrinich C, Weber E, Stirling R, Puy R, O'Hehir R, Douglass J. Omalizumab for anaphylaxis during hymenopteravenom immunotherapy [Poster 60]. Australasian Society of Clinical Immunology and Allergy (ASCIA) 21st Annual Scientific Meeting, 1-3 September 2010, Queensland. Internal Medicine Journal 2010;40(S4):20.
33. Akdis M, Akdis CA. Mechanisms of allergen-specific immunotherapy. Journal of Allergy and Clinical Immunology 2007;119(4):780-91.
34. Antonicelli L, Bilo MB, Bonifazi F. Epidemiology of Hymenoptera allergy. Current Opinion in Allergy and Clinical Immunology 2002;2(4):341-6.
35. Bilo MB, Bonifazi F. The natural history and epidemiology of insect venom allergy: clinical implications. Clinical and Experimental Allergy 2009;39(10):1467-76.
36. Bilo BM, Rueff F, Mosbech H, Bonifazi F, Oude Elberink JNG, EAACI Interest Group on Insect Venom Hypersensitivity. Diagnosis of Hymenoptera venom allergy. Allergy 2005;60(11):1339-49.
37. Bonadonna P, Perbellini O, Passalacqua G, Caruso B, Colarossi S, Dal Fior D, et al. Clonal mast cell disorders in patients with systemic reactions to Hymenoptera stings and increased serum tryptase levels. Journal of Allergy and Clinical Immunology 2009;123(3):680-6.
38. Bonifazi F, Jutel M, Bilo BM, Birnbaum J, Muller U, EACCI Interest Group on Insect Venom Hypersensitivity. Prevention and treatment of Hymenoptera venom allergy: guidelines for clinical practice. Allergy 2005;60(12):1459-70.
39. Brown SG. Clinical features and severity grading of anaphylaxis. Journal of Allergy & Clinical Immunology 2004;114(2):371-6.
40. Calderon MA, Boyle RJ, Penagos M, Sheikh A. Immunotherapy: The Meta-Analyses. What have we learned?. Immunology and Allergy Clinics of North America 2011;31(2):159-73.
41. Carballada F, Martin S, Boquete M. High efficacy and absence of severe systemic reactions after venom immunotherapy. Journal of Investigative Allergology and Clinical Immunology 2003;13(1):43-9.
42. Carballada FJ, Crehuet AM, Manjon HA, De La Torre F, Boquete M. Hymenoptera venom allergy: characterisitics, tolerance and efficacy of immunotherapy in the paediatric population. Allergologia et Immunopathologia 2009;37(3):111-5.
43. Carballada F, Boquete M, Nunez R, Lombardero M, De La Torre F. Follow-up of venom immunotherapy based on conventional techniques and monitoring of immunoglobulin E to individual venom allergens. Journal of Investigative Allergology and Clinical Immunology 2010;20(6):506-13.
44. Clark S, Camargo CA Jr. Epidemiology of anaphylaxis. Immunology and Allergy Clinics of North America 2007;27(2):145-63.
45. Ewan PW. New insight into immunological mechanisms of venom immunotherapy. Current Opinion in Allergy and Clinical Immunology 2001;1(4):367-74.
46. Freeman TM, Hylander R, Ortiz A, Martin ME. Imported fire ant immunotherapy: effectiveness of whole body extracts. Journal of Allergy & Clinical Immunology 1992;90(2):210-15.
47. Fricker M, Helbling A, Schwartz L, Muller U. Hymenoptera sting anaphylaxis and urticaria pigmentosa: clinical findings and results of venom immunotherapy in ten patients. Journal of Allergy and Clinical Immunology 1997;100(1):11-15.
48. Golden DB, Kagey-Sobotka A, Norman PS, Hamilton RG, Lichtenstein LM. Outcomes of allergy to insect stings in children, with and without venom immunotherapy. New England Journal of Medicine 2004;351(7):668-74.
49. Golden DB. Insect sting allergy and venom immunotherapy: a model and a mystery. Journal of Allergy & Clinical Immunology 2005;115(3):439-47.
50. Golden DB, Moffit J, Nicklas RA, Freeman T, Graft DF, Reisman RE, et al. Stinging insect hypersensitivity: a practice parameter update 2011. Journal of Allergy and Clinical Immunology 2011;127(4):852-4.
51. Haeberli G, Bronnimann M, Hunziker T, Muller U. Elevated basal serum tryptase and hymenoptera venom allergy: relation to severity of sting reactions and to safety and efficacy of venom immunotherapy. Clinical and Experimental Allergy 2003;33(9):1216-20.
52. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
53. Hockenhull JC, Elremeli M, Cherry MG, Mahon J, Lai M, Darroch J, et al. The clinical and cost effectiveness of pharmalgen for the treatment of bee and wasp venom allergy. Health Technology Assessment (in preparation).
54. Kalogeromitros D, Makris M, Koti I, Chliva C, Mellios A, Avgerinou G. A simple 3-day 'rush' venom immunotherapy protocol: documentation of safety. Allergologia et Immunopathologia 2010;38(2):69-73.
55. Krishna MT, Ewan PW, Diwakar L, Durham SR, Frew AJ, Leech SC, et al. Diagnosis and management of hymenoptera venom allergy: British Society for Allergy and Clinical Immunology (BSACI) guidelines. Clinical & Experimental Allergy 2011;41(9):1201-20.
56. Liew WK, Williamson E, Tang ML. Anaphylaxis fatalities and admissions in Australia. Journal of Allergy and Clinical Immunology 2009;123(2):434-42.
57. Moffitt JE, Golden DB, Reisman RE, Lee R, Nicklas R, Freeman T, et al. Stinging insect hypersensitivity: a practice parameter update. Journal of Allergy and Clinical Immunology 2004;114(4):869-86.
58. Mosbech H, Muller U. Side-effects of insect venom immunotherapy: results from an EAACI multicenter study. Allergy 2000;55(11):1005-10.
59. Mueller, HL . Diagnosis and treatment of insect sensitivity. Journal of Asthma Research 1966;3(4):331-3.
60. Muller U, Helbling A, Bischof M. Predictive value of venom-specific IgE, IgG and IgG subclass antibodies in patients on immunotherapy with honey bee venom. Allergy 1989;44(6):412-8.
61. Muller UR. Bee venom allergy in beekeepers and their family members. Current Opinion in Allergy and Clinical Immunology 2005;5(4):343-7.
62. Oude Elberink JNG, de Monchy JG, Golden DB, Brouwer JL, Guyatt GH, Dubois AEJ. Development and validation of a health-related quality-of-life questionnaire in patients with yellow jacket allergy. Journal of Allergy and Clinical Immunology 2002;109(1):162-70.
63. Oude Elberink JNG, Dubois AEJ. Quality of life in insect venom allergic patients. Current Opinion in Allergy and Clinical Immunology 2003;3(4):287-93.
64. Pumphrey RS. Lessons for management of anaphylaxis from a study of fatal reactions. Clinical and Experimental Allergy 2000;30(8):1144-50.
65. Radulovic S, Wilson D, Calderon M, Durham S. Systematic reviews of sublingual immunotherapy. Allergy 2011;66(6):740-52.
66. Ramirez DA, Londono S, Evans IRD. Adverse reactions to venom immunotherapy. Annals of Allergy 1981;47(6):435-9.
67. Rueff F, Przybilla B, Bilo MB, Muller U, Scheipl F, Aberer W, et al. Predictors of severe systemic anaphylactic reactions in patients with Hymenoptera venom allergy: importance of baseline serum tryptase-a study of the European Academy of Allergology and Clinical Immunology Interest Group on Insect Venom Hypersensitivity. Journal of Allergy and Clinical Immunology 2009;124(5):1047-54.
68. Sanchez-Machin I, Moreno C, Gonzalez R, Iglesias-Souto J, Perez E, Matheu, V . Safety of a 2-visit cluster schedule of venom immunotherapy in outpatients at risk of life-threatening anaphylaxis. Journal of Investigative Allergology and Clinical Immunology 2010;20(1):91-2.
69. Schiavino D, Nucera E, Pollastrini E, De Pasquale T, Buonomo A, Bartolozzi F, et al. Specific ultrarush desensitisation in hymenoptera venom-allergic patients. Annals of Allergy Asthma and Immunology 2004;92(4):409-13.
70. Senti G, Johansen P, Oliver R, Prinz Vavricka BM, Graf N, Wuthrich B, et al. A cutaneous allergen neutralisation test that correlates with the duration of venom immunotherapy. Internal Archives of Allergy and Immunology 2006;141(4):377-83.
71. Watanabe AS, Fonseca LA, Galvao CE, Kalil J, Castro FF. Specific immunotherapy using Hymenoptera venom: systematic review [Imunoterapia especifica com venenos de Hymenoptera: Revisao sistematica]. Sao Paolo Medical Journal. Revista Paulista de Medicina 2010;128(1):30-7.
72. Wilson AB, Deighton J, Lachmann PJ, Ewan PW. A comparative study of IgG subclass antibodies in patients allergic to wasp or bee venom. Allergy 1994;49(4):272-80.